Month: September 2024

Swedish telecommunications company Telia Company, AB, the largest shareholder of Telia Lietuva, AB (hereinafter ‘Telia Lietuva’ or ‘the Company’), holding 88.15 per cent of the Company’s shares, announces a change program that is set to simplify its operations in the Nordic and Baltic countries. The more decentralised and streamlined organisation will focus on local customers’ needs, while the Group intends to reduce its number of personnel by 3,000 during the full year of 2024. In Lithuania, Telia Company Group plans to reduce the total number of employees by about 400, whereof approximately 200 at Telia Lietuva, and remaining – at Telia Global Services Lithuania, UAB, a fully owned subsidiary of Telia Company in Lithuania. With the program, Telia Company aims to maximize the value of its network infrastructure and service offerings to...

SAMPO PLC                 STOCK EXCHANGE RELEASE                  4 September 2024 at 8:30 am Sampo plc’s share buybacks 3 September 2024 On 3 September 2024, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  7,478 40.93 AQEU          39,305 40.88 CEUX  2,154 40.87 TQEX  45,953 40.89 XHELTOTAL 94,890 40.89  *rounded to two decimals                 On 17 June 2024, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which...

Press ReleaseNicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from BoardChristine Placet is CFO of Theranexus, and was formerly CEO of Horama and Trophos Michele Garufi, former Chairman and CEO of Nicox, hands over his Board position after over more than 25 years at the company he co-founded The Nicox Board has now been entirely renewed to bring in the expertise to support the Company’s strategic direction going forwardSeptember 4th, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that Michele Garufi is stepping down as a member of the Board of Directors. The Board has appointed Christine Placet, a deeply experienced CEO and financial leader in the biotech industry, as a new Board...

PRESS RELEASE Regulated Information Antwerp, Belgium, 4 September 2024 (07.00 a.m. CET) VGP NV (‘VGP’ or ‘the Group’), a European provider of high-quality logistics and semi-industrial real estate, has had its credit rating reaffirmed by the Rating Agency Fitch Ratings (‘Fitch’). Fitch has reaffirmed the credit rating for VGP NV with a Long-Term Issuer Default Rating (IDR) and senior unsecured rating at ‘BBB-‘. The Outlook on the rating is Stable. Fitch stated: “The ratings reflect VGP’s continued discipline in managing development risk, from land location and price, the quality of units built, pre-lets, its development profit headroom, to completion when new properties are sold to pre-funded dedicated 50-50 joint ventures (JVs).” For further details and the full rating report please refer to the Fitch corresponding press...

Geneva, Switzerland, September 4, 2024 – Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9 – 11, 2024, at the Lotte New York Palace Hotel. A pre-recorded video presentation by Mr. Dyer in which he provides a corporate update and discusses recent developments at Addex, will be available for viewing on-demand from 07:00 EDT on Monday, September 9, 2024, via the following webcast link. Mr. Dyer will be available for one-on-one meetings throughout the conference. For more information or to schedule a meeting, please contact IR@addexpharma.com. About Addex:Addex...

Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September:2024 Wells Fargo Healthcare Conference, Boston, September 4-6Sijmen de Vries, Chief Executive Officer, will participate in a fireside chat question and answer session on Friday, September 6 at 08:45 AM ET/14:45 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website. H.C. Wainwright 26th Annual Global Investment Conference, New York, September 9-11Sijmen de Vries, Chief Executive Officer, will present on Monday, September 9 at 10:30 AM ET/16:30 CET. A live webcast and replay of the presentation will be available...

CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX: CNE; OTCQX: CNNEF; BVC: CNEC) is pleased to announce that, on September 3, 2024, it entered into a committed 24 month US $75 million senior secured term loan facility (the “Facility”) with Macquarie Group (“Macquarie”). The initial draw on funding is expected to be US $50 million, with a further commitment of US $25 million available for a twelve month period should certain production metrics be met. The Facility bears an annual interest rate of SOFR + 8.0% on drawn amounts and 2.4% on undrawn amounts during the commitment period. The Corporation expects to enter a SOFR hedging agreement with Macquarie fixing the interest rate. The Facility matures on September 3, 2026, and has a twelve month principal payment grace period....

TORONTO, Sept. 03, 2024 (GLOBE NEWSWIRE) — PTX Metals Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PF) (“PTX Metals” or the “Company”) announces that it will be proceeding with the consolidation of its common shares (the “Common Shares”) on the basis of four (4) pre consolidated Common Shares into one (1) post consolidated Common Share (the “Share Consolidation”) approved by shareholders on July 13, 2022. The Company has made progress in advancing its mineral projects and expects that the Share Consolidation will provide greater flexibility as it continues to develop these projects. Additionally, the Company anticipates that the Share Consolidation will align shareholders for the potential distribution of Common Shares in its subsidiaries. The Company currently has 370,213,062 common shares outstanding, and, accordingly, expects...

LA JOLLA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract was accepted for presentation regarding a clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS Phase 2b/ 3 study at the 2024 Annual NEALS Meeting to be held October 21-24, 2024 (a hybrid meeting in Clearwater, Florida and Online). The presentation will be in poster format and be presented by lead Principal Investigator of the clinical trial, Björn Oskarsson, MD, FAAN, Associate Professor of Neurology at Jacksonville, FL and Director, ALS Center of Excellence. The presentation details are as follows: Submission ID: 164 Title: COMBAT-ALS Phase 2b/3...